{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T02:40:51Z","timestamp":1715308851551},"reference-count":50,"publisher":"IntechOpen","isbn-type":[{"value":"9781789852172","type":"print"},{"value":"9781789852189","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.5772\/intechopen.76500","type":"book-chapter","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T09:45:05Z","timestamp":1549532705000},"source":"Crossref","is-referenced-by-count":1,"title":["Management of Multiple Myeloma in Developing Countries"],"prefix":"10.5772","author":[{"given":"Ogbonna","family":"Collins Nwabuko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Parkin DM, Bray F, Ferley J, Pisani P. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2002;55(2):74-108","DOI":"10.3322\/canjclin.55.2.74"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: A Cancer Journal for Clinicians. 2009;59(4):225-249","DOI":"10.3322\/caac.20006"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma. A prospective study. Blood. 2009;113(22):5412-5417","DOI":"10.1182\/blood-2008-12-194241"},{"key":"ref=4","unstructured":"Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Clinical\u00a0Haematology. 2007;20(4):637-636"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Alexander DD, Mink PJ, Adami H, et al. Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer. 2007;120(suppl 12):40-61","DOI":"10.1002\/ijc.22718"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Nwabuko OC, Igbigbi EE, Chukwuonye II, Nnoli MA. Multiple myeloma in Niger Delta, Nigeria: Complications and the outcome of palliative interventions. Cancer Management and Research. 2017;9:189-196. Available from: http:\/\/www.dovepress.com\/doi.org\/10.2147\/CMAR.S126136 [Accessed: May 30, 2017]","DOI":"10.2147\/CMAR.S126136"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Larson D, Kyle RA. Diagnosis of smouldering multiple myeloma. The New England Journal of Medicine. 2011;365(5):474-475 [Epub: August 5, 2011]","DOI":"10.1056\/NEJMc1106428"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance (MGUS) in the agriculture health study. Blood. 2009;113(25):6386-6391","DOI":"10.1182\/blood-2009-02-203471"},{"key":"ref=9","unstructured":"Myeloma. In: Litchman MA, Kaushansky K, Prchal JT, Marcel ML, Burns JL, Armitage JO, editors. Williams Manual of Hematology. 9th ed. New York: McGraw-Hill Education; 2017.pp. 634-662"},{"key":"ref=10","unstructured":"Ghobrial IM, Lacy MQ. Plasma cell disorders. In: McCrae KR, Steenma DP, editors. American Society of Hematology Self-Assessment Program. 5th ed. Richmond: Cadmos Communication; 2017. pp. 634-662"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clinic Proceedings. 2005;80(10):1371-1382","DOI":"10.4065\/80.10.1371"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Durie BGM, Salmon SE. A Clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36(3):75, 842-854","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005 May 20;23(15):3412-3420","DOI":"10.1200\/JCO.2005.04.242"},{"key":"ref=14","unstructured":"Nwabuko OC, Igbigbi EE, Okoh DA. Plasma cell myeloma: Challenges in diagnosis in sub-Saharan Africa. Jokull Journal. 2015;65(1):254-266"},{"key":"ref=15","unstructured":"Omoti C, Halim NKD. Plasma cell myeloma in a tertiary Center in Niger-Delta Region of Nigeria: Clinico-immunologic analysis. Pakistan Journal of Medical Sciences. 2007;23(1):27-32"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Salawu L, Durosimi MO. Myelomatosis: Clinical and laboratory features in Nigeria. West African Journal of Medicine. 2005;24(1):54-57","DOI":"10.4314\/wajm.v24i1.28164"},{"key":"ref=17","unstructured":"Fasola FA, Eteng K, Akinyemi JO. Multiple myeloma: Challenges of management in a developing country. Journal of Medical Sciences. 2008:397-403"},{"key":"ref=18","unstructured":"Altekruse SF, Kosary CL, Krapch M. SEER. Cancer Statistics Review. 1975-2007. Bethesda: National Cancer Institute; 2010. Available from: seer.cancer.gov\/statfacts\/html\/mulmy.html [Accessed: April 14,2017]"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569-4575","DOI":"10.1182\/blood-2002-10-3017"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe francophone du Myelome. Blood. 2007;109:3489-3495","DOI":"10.1182\/blood-2006-08-040410"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Garret JR, Durie BGM, Nedwin GE, et al. Production of lymphotoxin, a bone resorbing cytokine by cultured human myeloma cells. The New England Journal of Medicine. 1989;317(9):526-532","DOI":"10.1056\/NEJM198708273170902"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Annibali AO et al. Cytokines behavior in multiple myeloma patients during Zoledronic acid treatment. Journal of Blood and Lymph. 2017;7(4):184","DOI":"10.4172\/2165-7831.1000184"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. British Journal of Haematology. 1992;82(4):648-653","DOI":"10.1111\/j.1365-2141.1992.tb06939.x"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Sepulveda C, Marlin A, Yoshida T, Ulrich A. Palliative care: World Health Organization\u2019s global perspective. The Journal of Pain and Symptom Management. 2002;24:91-96","DOI":"10.1016\/S0885-3924(02)00440-2"},{"key":"ref=25","unstructured":"Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975\u20132002, Bethesda, MD: National Cancer Institute; 2005. Based on November 2004 SEER data submission, posted to the SEER web site 2005; Myeloma section. Available from: http:\/\/seer.cancer.gov\/csr\/1975_2002\/ [Accessed April 14, 2017]"},{"key":"ref=26","unstructured":"Altekruse SF, Kosary CL, Krapcho M. SEER Cancer Statistics Review. 1975\u20132007. Bethesda: National Cancer Institute; 2010. Reviewed from: seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"ref=27","unstructured":"World Health Organization. Traitement de la douleur cancereuse. Geneva: World Health Organization; 1987"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Evangelos T, Gareth M, Meletios AD, et al. International myeloma working group recommendations for the treatment of multiple-myeloma related bone disease. Journal of Clinical Oncology. 2013;31(18):2347-2357","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Nwankwo KC, Dawotola DA, Sharma V. Radiotherapy in Nigeria: Current status and future challenges. The West African Journal of Radiology. 2013;20:84-88","DOI":"10.4103\/1115-1474.121099"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Nwokeukwu IH, Nwabuko OC, Chuku A, Ajuogu E, Okoh DA. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis in blood donors in a tertiary health facility in south eastern Nigeria. Hematology and Leukemia. 2014;2:4","DOI":"10.7243\/2052-434X-2-4"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Madu AJ, Ochenis S, Nwagha TA, Ibegbulam OG, Anike US. Multiple myeloma in Nigeria: An insight to the clinical, laboratory features, and outcomes. Nigeria Journal of Clinical Practice. 2014;17(2):212-217","DOI":"10.4103\/1119-3077.127561"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Badros A, Barlogie B, Siegel E, Robert J, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. British Journal of Haematology. 2001;114(4):822-829. DOI: 10.1046\/j.1365-2141.2001.03033.x","DOI":"10.1046\/j.1365-2141.2001.03033.x"},{"key":"ref=33","unstructured":"Kar M, Roy R, Chakraborty J, Das S. Extramedullary plasmacytoma\u2014A rare presentation. Journal Indian Academy of Clinical Medicine. 2008;9(4):229"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews. Cancer. 2007;7:585-598","DOI":"10.1038\/nrc2189"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Darly T, Wee Joo C, Takaaki C, et al. Management of multiple myeloma in Asia: Resource-stratified guidelines. The Lancet. 2013;14(12):e571-e581","DOI":"10.1016\/S1470-2045(13)70404-2"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG SO777): A randomized, open-label, phase 3 trial. Lancet. 2017;389:519-527","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679-686","DOI":"10.1182\/blood-2010-02-268862"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. Journal of the National Comprehensive Cancer Network. 2011;9:1146-1183","DOI":"10.6004\/jnccn.2011.0095"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Korubo KI, Madu AJ, Okoye H, Nwogoh B. Bortezomib prescription pattern for the treatment of multiple myeloma by hematologists in Nigeria. Journal of Global Oncology. 2017. DOI: 10.1200\/JGO.17.00033. Published online before print November 1, 2017","DOI":"10.1200\/JGO.17.00033"},{"key":"ref=40","unstructured":"Nwabuko OC, Nnoli MA, Okoh DA, John EJ, Chukwuonye II. Survival outcome of multiple myeloma patients on chemotherapeutic regimens in the Niger-Delta Nigeria. International Journal of Recent Scientific Research. 2015;6(6):4889-4893"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Uzochukwu BS, Ughasoro MD, Etiaba E, et al. Health care financing in Nigeria: Implications for achieving universal health coverage. Nigerian Journal of Clinical Practice. 2015;18:437-444","DOI":"10.4103\/1119-3077.154196"},{"key":"ref=42","unstructured":"Oyekunle AA. Haematopoietic stem cell transplantation: Prospects and challenges in Nigeria. Annals of Ibadan Postgraduate Medicine. 2006;4(1):17-27"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Bazuaye GN. Challenges of setting up the first stem cell transplantation Center in a Developing Country (Nigeria). International Journal of Tropical Disease and Health. 2013;3(4):292-299","DOI":"10.9734\/IJTDH\/2013\/4760"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Olaniyi JA, Fowodu FO. Multiple myeloma: The burden and clinico-laboratory characteristics in a Nigerian foremost tertiary hospital. Journal of Applied Hematology. 2015;6(2):58-63","DOI":"10.4103\/1658-5127.160200"},{"key":"ref=45","unstructured":"Wannesson L, Panzarella T, Mikhael J, Keating A. Feasibility and safety of autotransplant with noncryopreserved marrow or peripheral blood stem-cells: A systemic review. Annals of Oncology. 2007 (April 1);18(4):623-632. DOI: 10.1093\/annal\/mdm069"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Al-Anazi KA. Autologous hematopoietic stem cell transplantation for multiple myeloma without cryopreservation. Bone Marrow\u00a0Research. 2012;2012:917361. DOI: 10.1155\/2012\/917361. Epub: May 28, 2012","DOI":"10.1155\/2012\/917361"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G, Barlogie B. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplantation. 1997 Sep;20(6):445-450","DOI":"10.1038\/sj.bmt.1700900"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Paul TM, Liu SV, Chong EA, et al. Outpatient Autologous Stem Cell Transplantation for Patients with Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2015 Sept; 15(9):536-540. DOI: 10.1016\/j.clml.2015.05.006. Epub: June 16, 2015","DOI":"10.1016\/j.clml.2015.05.006"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Graff TM, Singavi AK, Schmidt W, et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplantation. 2015 Jul;50(7):947-953. DOI: 10.1038\/bmt.2015.46","DOI":"10.1038\/bmt.2015.46"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Holbro A, Ahmed I, Cohen S, et al. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. Biology of Blood\u00a0and\u00a0Marrow Transplantation. 2013 April;19(4):547-551. DOI: 10.1016\/j.bbmt.2012.12.006","DOI":"10.1016\/j.bbmt.2012.12.006"}],"container-title":["Update on Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/61996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T07:59:23Z","timestamp":1550649563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/books\/update-on-multiple-myeloma\/management-of-multiple-myeloma-in-developing-countries"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"ISBN":["9781789852172","9781789852189"],"references-count":50,"URL":"https:\/\/doi.org\/10.5772\/intechopen.76500","relation":{},"subject":[],"published":{"date-parts":[[2019,2,20]]}}}